Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
Year: 2021
Type: article
Abstract: How the Delta variant evades defenses In the course of the COVID-19 epidemic, variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, some of which evade immunity or increase transmission. In late 2020, the Delta and Kappa variants were detected, and the Delta variant became globally dominant by June 2021. McCallum et al . show that vaccine-elicited serum-neutralizing activity is reduced against these variants. Based on biochemistry and structural studies, the authors show that mutations in the domain that binds the ACE2 receptor abrogate binding to some monoclonal antibodies but do not improve ACE2 binding, suggesting that they emerged to escape immune recognition. Remodeling of the N-terminal domain allows the variants to escape recognition by most neutralizing antibodies that target it. The work could guide the development of next-generation vaccines and antibody therapies. —VV
Source: Science
Authors: Matthew McCallum, Alexandra C. Walls, Kaitlin R. Sprouse, John E. Bowen, Laura Rosen, Ha V. Dang, Anna deMarco, Nicholas Franko, Sasha W Tilles, Jennifer Logue, Marcos C. Miranda, Margaret Ahlrichs, Lauren Carter, Gyorgy Snell, Matteo Samuele Pizzuto, Helen Y. Chu, Wesley C. Van Voorhis, Davide Corti, David Veesler
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Awards: University of Washington Arboviral Research Network (UWARN), G1580077915, G276384829, Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeutics, Acquisition of a high resolution, high throughput cryo-electron microscope, G7848094000
OpenAlex ID: W3214683033
